Research graph
References from Fosfomycin as Oral Transition Therapy Versus Continued Intravenous β-Lactams for Complicated Urinary Tract Infections Caused by Extended-Spectrum β-Lactamase–Producing Enterobacterales : A Multicenter, Open-Label, Randomized Controlled Trial. Local targets link to admitted publications; unresolved targets remain external evidence.
Urinary tract infections in the elderly: a review of disease characteristics and current treatment options
10.7573/dic.2020-4-13 · 2020 · External reference
Extended-spectrum beta-lactamase-producing Enterobacteriaceae: an emerging public-health concern
10.1016/s1473-3099(08)70041-0 · 2008 · External reference
Defining an extended-spectrum beta-lactamase
10.1111/j.1469-0691.2007.01857.x · 2008 · External reference
Bacteremia due to extended-spectrum beta-lactamase-producing Escherichia coli in the CTX-M era: a new clinical challenge
10.1086/508877 · 2006 · External reference
The management of multidrug-resistant Enterobacteriaceae
10.1097/qco.0000000000000314 · 2016 · External reference
Fourteen years in resistance
10.1016/j.ijantimicag.2011.12.012 · 2012 · External reference
Infectious Diseases Society of America 2024 guidance on the treatment of antimicrobial-resistant gram-negative infections
10.1093/cid/ciae403 · External reference
Effect of piperacillin-tazobactam vs meropenem on 30-day mortality for patients with E coli or Klebsiella pneumoniae bloodstream infection and ceftriaxone resistance: a randomized clinical trial
10.1001/jama.2018.12163 · 2018 · External reference
Current options for the treatment of infections due to extended-spectrum beta-lactamase-producing Enterobacteriaceae in different groups of patients
10.1016/j.cmi.2019.03.030 · 2019 · External reference
β-Lactam/β-lactam inhibitor combinations for the treatment of bacteremia due to extended-spectrum β-lactamase-producing Escherichia coli: a post hoc analysis of prospective cohorts
10.1093/cid/cir790 · 2012 · External reference
Fosfomycin: use beyond urinary tract and gastrointestinal infections
10.1086/527442 · 2008 · External reference
Multiple-dose oral fosfomycin for treatment of complicated urinary tract infections in the outpatient setting
10.1093/ofid/ofaa034 · 2020 · External reference
Daily fosfomycin versus levofloxacin for complicated urinary tract infections
10.1128/mbio.01677-23 · 2023 · External reference
Fosfomycin
10.1128/cmr.00068-15 · 2016 · External reference
Phase I study to evaluate the pharmacokinetics, safety, and tolerability of two dosing regimens of oral fosfomycin tromethamine in healthy adult participants
10.1128/aac.00464-18 · 2018 · External reference
Effectiveness of fosfomycin for the treatment of multidrug-resistant Escherichia coli bacteremic urinary tract infections: a randomized clinical trial
10.1001/jamanetworkopen.2021.37277 · 2022 · External reference
Unresolved reference
2025 · External reference
In vitro susceptibility of multi-drug resistant Klebsiella pneumoniae strains causing nosocomial infections to fosfomycin. A comparison of determination methods
10.3390/pathogens10050512 · 2021 · External reference
Fosfomycin vs ciprofloxacin as oral step-down treatment for Escherichia coli febrile urinary tract infections in women: a randomized, placebo-controlled, double-blind, multicenter trial
10.1093/cid/ciab934 · 2022 · External reference
Fosfomycin for injection (ZTI-01) versus piperacillin-tazobactam for the treatment of complicated urinary tract infection including acute pyelonephritis: ZEUS, A phase 2/3 randomized trial
10.1093/cid/ciz181 · 2019 · External reference
Antimicrobial susceptibilities of clinical bacterial isolates from urinary tract infections to fosfomycin and comparator antibiotics determined by agar dilution method and automated micro broth dilution
10.1128/spectrum.01860-24 · 2025 · External reference
Comparison of fosfomycin to ertapenem for outpatient or step-down therapy of extended-spectrum β-lactamase urinary tract infections
10.1016/j.ijantimicag.2016.04.014 · 2016 · External reference
Oral fosfomycin for treatment of urinary tract infection: a retrospective cohort study
10.1186/s12879-016-1888-1 · 2016 · External reference
Oral treatment options for patients with urinary tract infections caused by extended spectrum βeta-lactamase (ESBL) producing Enterobacteriaceae
10.1016/j.jiph.2019.05.012 · 2019 · External reference
Oral and intravenous fosfomycin for the treatment of complicated urinary tract infections
10.1155/2020/8513405 · 2020 · External reference
Fosfomycin in the treatment of extended spectrum beta-lactamase-producing Escherichia coli-related lower urinary tract infections
10.1016/j.ijantimicag.2006.08.039 · 2007 · External reference
Carbapenem versus fosfomycin tromethanol in the treatment of extended-spectrum beta-lactamase-producing Escherichia coli-related complicated lower urinary tract infection
10.1179/joc.2010.22.5.355 · 2010 · External reference
Evaluation of three-dose fosfomycin tromethamine in the treatment of patients with urinary tract infections: an uncontrolled, open-label, multicentre study
10.1136/bmjopen-2013-004157 · 2013 · External reference
Efficacy and safety of oral fosfomycin for urinary tract infections in hospitalized patients
10.1128/aac.02971-15 · 2016 · External reference
The use of oral fosfomycin-trometamol in patients with catheter-associated urinary tract infections (CAUTI): new indications for an old antibiotic?
10.1080/1120009x.2018.1500110 · 2018 · External reference
Treatment of complicated urinary tract infection in adults: combined analysis of two randomized, double-blind, multicentre trials comparing ertapenem and ceftriaxone followed by appropriate oral therapy
10.1093/jac/dkh208 · 2004 · External reference
Unresolved reference
External reference
Fosfomycin tromethamine. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy as a single-dose oral treatment for acute uncomplicated lower urinary tract infections
10.2165/00003495-199753040-00007 · 1997 · External reference
Effect of 5-day nitrofurantoin vs single-dose fosfomycin on clinical resolution of uncomplicated lower urinary tract infection in women: a randomized clinical trial
10.1001/jama.2018.3627 · 2018 · External reference
Oral fosfomycin use for pyelonephritis and complicated urinary tract infections: a 1 year review of outcomes and prescribing habits in a large municipal healthcare system
10.1093/jac/dkaa126 · 2020 · External reference
Fosfomycin vs ertapenem for outpatient treatment of complicated urinary tract infections: a multicenter, retrospective cohort study
10.1093/ofid/ofab620 · 2022 · External reference
In vitro activity of fosfomycin against Escherichia coli isolated from patients with urinary tract infections in Canada as part of the CANWARD surveillance study
10.1128/aac.02399-13 · 2014 · External reference
Susceptibility of Escherichia coli from community-acquired urinary tract infection to fosfomycin, nitrofurantoin, and temocillin in Korea
10.3346/jkms.2014.29.8.1178 · 2014 · External reference
The ARESC study: an international survey on the antimicrobial resistance of pathogens involved in uncomplicated urinary tract infections
10.1016/j.ijantimicag.2009.04.012 · 2009 · External reference
In vitro effect of fosfomycin on multi-drug resistant gram-negative bacteria causing urinary tract infections
10.2147/idr.s207569 · 2019 · External reference
Experience with fosfomycin in the treatment of complicated urinary tract infections caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae
2019 · External reference
Fosfomycin for treatment of multidrug-resistant pathogens causing urinary tract infection: a real-world perspective and review of the literature
10.1016/j.diagmicrobio.2019.06.008 · 2019 · External reference
Guidelines for the prevention, diagnosis, and management of urinary tract infections in pediatrics and adults: a WikiGuidelines group consensus statement
10.1001/jamanetworkopen.2024.44495 · 2024 · External reference
A randomized controlled trial of sitafloxacin vs. ertapenem as a switch therapy after treatment for acute pyelonephritis caused by extended-spectrum β-lactamase-producing Escherichia coli: a pilot study
10.1016/j.jiac.2017.05.005 · 2017 · External reference
A randomized, controlled trial of prulifloxacin as conversion therapy after intravenous carbapenem in the treatment of acute pyelonephritis caused by third generation cephalosporin resistant pathogens: a pilot study
10.1111/cts.13665 · 2023 · External reference
Early discharge of hospitalised patients with community-acquired urosepsis when treated with levofloxacin in sequential therapy
2006 · External reference
Short-term effectiveness of ceftriaxone single dose in the initial treatment of acute uncomplicated pyelonephritis in women. A randomised controlled trial
10.1136/emj.19.1.19 · 2002 · External reference
Randomized trial of oral versus sequential IV/oral antibiotic for acute pyelonephritis in children
10.1542/peds.2011-0814 · 2012 · External reference
Unresolved reference
External reference
Antibiotic treatment for 7 versus 14 days in patients with bloodstream infections
10.1056/nejmoa2404991 · 2025 · External reference
